ArticleAdvanced healthcare materials2019
Dendritic Cell Membrane Vesicles for Activation and Maintenance of Antigen-Specific T Cells.
Article in Advanced healthcare materials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Immune cell-derived membrane nanovesicles: A promethean fire for autoimmune disease therapy through immune cell mimicry.Bioactive materials · 2026Review
- Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook.Acta pharmaceutica Sinica. B · 2026Review
- Personalized Cancer Immunotherapy Boosted by cGAS-STING-Targeted Nanovaccines in Combination With Nutrient Modulation.Exploration (Beijing, China) · 2025Article
- Engineering dendritic cell biomimetic membrane as a delivery system for tumor targeted therapy.Journal of nanobiotechnology · 2024Review
- Causal role of immune cells in aplastic anemia: Mendelian randomization (MR) study.Scientific reports · 2024Article
- Cellular-Membrane-Derived Vesicles for Cancer Immunotherapy.Pharmaceutics · 2023Review
- Lipid-hybrid cell-derived biomimetic functional materials: A state-of-the-art multifunctional weapon against tumors.Materials today. Bio · 2023Review
- Cellular nanovesicles for therapeutic immunomodulation: A perspective on engineering strategies and new advances.Acta pharmaceutica Sinica. B · 2023Review
- Article
- Cell-Derived Vesicles for Nanoparticles' Coating: Biomimetic Approaches for Enhanced Blood Circulation and Cancer Therapy.Advanced healthcare materials · 2022Review
- Immunotheranostic microbubbles (iMBs) - a modular platform for dendritic cell vaccine delivery applied to breast cancer immunotherapy.Journal of experimental & clinical cancer research : CR · 2022Article
- Cell membrane coated-nanoparticles for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2022Review
- Engineered cancer cell membranes: An emerging agent for efficient cancer theranostics.Exploration (Beijing, China) · 2022Review
- The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma.Frontiers in molecular biosciences · 2022Review
- Cell Membrane-Derived Vesicle: A Novel Vehicle for Cancer Immunotherapy.Frontiers in immunology · 2022Review
- Engineered Cell Membrane-Derived Nanoparticles in Immune Modulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Protective and Therapeutic Effects of an IL-15:IL-15Rα-Secreting Cell-Based Cancer Vaccine Using a Baculovirus System.Cancers · 2021Article
- Cell membrane-derived vesicles for delivery of therapeutic agents.Acta pharmaceutica Sinica. B · 2021Review
- Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy.Biomaterials · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cell membranes have recently gained attention as a promising drug delivery system. Here, dendritic cell membrane vesicles (DC-MVs) are examined as a platform to promote T cell responses. Nanosized DC-MVs are derived from DCs pretreated with monophosphoryl lipid A (MPLA), a FDA-approved immunostimulatory adjuvant. These "mature" DC-MVs activate DCs in vitro and increase their expression of costimulatory markers. DC-MVs also promote cross-priming of antigen-specific T cells in vitro, increasing their survival and CD25 expression. In addition, these mature DC-MVs potently augment the expansion of adoptively transferred CD8+ T cells in vivo, generating twofold to fourfold higher frequency of antigen-specific T cells, compared with other control formulations, including "immature" DC-MVs obtained without the MPLA pretreatment. Taken together, these results suggest that DC-MVs are an effective delivery platform for T cell activation and may serve as a potential delivery system for improving adoptive T cell therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.